Yanfang Feng Honoured With 2019 Outstanding Postdoctoral Fellow Award at the 17th World Congress of the International Photodynamic Association Print E-mail
By GLOBE NEWSWIRE   
Thursday, 11 July 2019 10:23

Boston, USA, July 11, 2019 (GLOBE NEWSWIRE)

Boston, USA, July 11, 2019 (GLOBE NEWSWIRE) -- At the 17th International Photodynamic Association World Congress in Boston, Massachusetts, Dr. Yanfang Feng was recognized with the 2019 Outstanding Postdoctoral Fellow Award.

The IPA Outstanding Postdoctoral Fellow Award recognizes a postdoctoral scholar, fellow or postdoctoral research associate for excellence in scientific research, innovation, leadership, outreach and service in the field of photodynamic therapy (PDT). Dr. Feng is a Postdoctoral Fellow at the Wellman Center for Photomedicine, Massachusetts General Hospital & Harvard Medical School who is currently working on rapid and low-cost diagnosis and treatment of antibiotic resistant pathogens using photomedicine. She has initially focused on PDT-related therapies to address carbapenemase-producing pathogens, a serious health threat given the extent of antimicrobial resistance.

IPA World Congress

The Boston World Congress was the 17th conference held by the International Photodynamic Association, marking 34 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The Boston World Congress was led by Congress Chair and IPA President Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT) and had record attendance with representatives from 33 countries.  The 2021 IPA World Congress will be hosted in Moscow, Russia and the 2023 IPA World Congress will be held in Shanghai, China.

About Photodynamic Therapy

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types and stages of cancers and pre-cancers, macular degeneration and multidrug-resistant infections involving bacteria, viruses and fungi. First developed in the 1980s, PDT has demonstrated superior patient outcomes with considerable cost savings. Over the past 30 years, millions of patients globally have been successfully treated with PDT.

About the International Photodynamic Association

The International Photodynamic Association (IPA) was founded in 1986 to support and endorse the scientific advancement and clinical development of photodynamic therapy and photodiagnosis. With members and associates from over 30 countries, the IPA represents a truly global community consisting of prominent international scientists, clinicians and translational researchers, healthcare professionals and students across academic, hospital, government and private sector organizations. The IPA promotes the study of diagnosis and treatment using light-activated photosensitizers and disseminates scientific information to its members, the research community, and to the community at large. The IPA organizes a biennial World Congress around the world, providing members and non-members a unique opportunity to share and learn more about global developments relating specifically to photodynamic therapy and photodiagnosis. 

For further information: [email protected]

Attachment

Angelika Vance  International Photodynamic Association  6048382702  [email protected]  



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter